Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BMO Capital Downgrades Tourmaline Bio to Market Perform, Raises Price Target to $48

Author: Benzinga Newsdesk | September 15, 2025 05:16am
BMO Capital analyst Kostas Biliouris downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and raises the price target from $35 to $48.

Posted In: TRML


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist